|Abbott Laboratories -- Brazil Stock|| |
BRL 43.36 0.00 0.00%
Executive VP of Ventures
Dr. John M. Capek, Ph.D. is Executive Vice President Ventures of the Company. Previously, he served as Senior Vice President, Abbott Vascular, heading up Abbott global vascular business. Dr. Capek served in various management roles at Guidant, including president, Guidant Vascular Intervention and Vice President and General Manager of Bioabsorbable Vascular Solutions. He also served as Vice President and General Manager of Guidant Germany and Vice President, Marketing, Guidant Cardiac Rhythm Management Group. Before joining Guidant, Dr. Capek was manager of New Product Technology at Eli Lilly Company
Age: 54 EVP Since 2015
Capek has a Bachelor degree in Biomedical Engineering, a Master degree in Biomedical Engineering, a Master degree in Electrical Engineering, a Ph.D. in Biomedical Engineering and a Master degree in Business Administration from Rensselaer Polytechnic Institute.
The company has return on total asset (ROA)
of 3.45 %
which means that it generated profit of $3.45 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 4.05 %
meaning that it generated $4.05 on every $100 dollars invested by stockholders.
The company has accumulated 24.09 B in total debt with debt to equity ratio (D/E) of 75.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Abbott Laboratories has Current Ratio of 2.88 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Abbott Laboratories manufactures and sells health care solutions worldwide. Abbott Laboratories (ABTT34) is traded on Sao Paolo Stock Exchange in Brazil. It is located in Abbott Park, IL and employs 74,000 people.